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Determining need for liver transplantation (LT) can be
effectively estimated when the actual liver disease is
highly likely to cause death in the near future. However,
for many conditions, the liver disease itself does not
carry a high risk of short-term mortality, and other
factors contribute to defining the need for LT. The exis-
tence of these so-called exceptional cases was recog-
nized in the initial development of the Model for End-
Stage Liver Disease (MELD)- and Pediatric End-Stage
Liver Disease (PELD)-based liver allocation policy,1
most notably in the case of hepatocellular cancer
(HCC). In this instance, the driving imperative for LT is
not life-threatening liver failure, but the progression of
cancer to a point where a high probability of cure is no
longer possible. Using the well-established Milan Crite-
ria2 as selection criteria for good outcome, policymak-
ers initially equated the risk of HCC progression beyond
Milan Criteria to 15% for stage 1 lesions and 30% for
stage 2 lesions within 3 months of listing analogous to
MELD-defined mortality risk.3 These initial estimates
proved to be too high based on publications citing much
lower risks of progression in cohorts of waiting LT can-
didates with HCC,4,5 and subsequently, the risk of HCC
progression was reestimated to be much lower. The
HCC priority policy was revised accordingly.
The HCC example illustrates two important princi-
ples for allocating livers to patients with low mortality
risk who fall into these exceptional diagnosis catego-
ries. First, a nonmortality endpoint, namely the risk of
progression beyond Milan Criteria, where a patient
would be removed from the LT waiting list, was defined.
For any such endpoint, patient-specific, objective defi-
nitions must be used. In the case of HCC, the risk of
tumor progression beyond the Milan Criteria meets
such standards because the risk of progression does
not depend on extrinsic influences like geography, lo-
Abbreviations: LT, liver transplantation; MELD, Model for End-Stage Liver Disease; PELD, Pediatric End-Stage Liver Disease; HCC,
hepatocellular cancer; RRB, Regional Review Board; MESSAGE, MELD Exceptional Case Guideline, HE, hepatic encephalopathy;
BCS, Budd-Chiari syndrome; PH, primary hyperoxaluria; CF, cystic fibrosis.
Address reprint requests to Robert G. Gish, MD, 2340 Clay Street, Room 223, California Pacific Medical Center, San Francisco, CA 94115.
Telephone: 415-600-1020 or -1022; FAX: 415-776-0292; E-mail: gishr@sutterhealth.org and Richard B. Freeman, Jr., MD, Division of Transplant
Surgery, Tufts-New England Medical Center, Box 40, 750 Washington Street, Boston, MA 02111. Telephone: 617-636-5592; FAX: 617-636-8228;
E-mail: rfreeman@tufts-nemc.org
DOI 10.1002/lt.20979
Published online in Wiley InterScience (www.interscience.wiley.com).
LIVER TRANSPLANTATION 12:S128-S136, 2006
S128 Liver Transplantation, Vol 12, No 12, Suppl 3 (December), 2006: pp S128-S136
cation of care, or subjective assessment of symptoms,
and the Milan criteria are very well described and rea-
sonably measurable. Policymakers may change the
HCC endpoint in the future on the basis of recent evi-
dence that there are some cases beyond Milan Criteria
that also carry excellent disease-free survival after LT.
Doing so, however, would not require a complete revi-
sion of the liver allocation system but would only re-
quire reestimation of the risk of progression to this new
endpoint. Thus, endpoints can be revised over time if
they remain appropriate, objective, and patient-specific
estimates of need, and continue to define reasonable
success rates relative to the majority of waiting candi-
dates. This process is critical for maintenance of equity
of access to the limited donor pool. Second, as evidence
accumulated, the original, admittedly arbitrary, esti-
mates of risks of achieving the beyond–Milan Criteria
endpoint were not as high as originally thought, and
again, the assigned priority was changed based on ev-
idence and without the need to completely readjust the
entire system. More recently, with additional accumu-
lated experience, investigators have more directly esti-
mated the risk of HCC progression by using waiting list
removal data.6 In this effort, factors associated with
waiting list removal for candidates with HCC were iden-
tified and used to construct a predictive model for wait-
ing-list dropout, which can be used to more accurately
estimate risk of waiting list removals. This approach
can serve as a framework for all LT candidates where
the estimated risk of removal can be calculated once
criteria for such removals are established. These re-
moval criteria we term “waiting list endpoints” and can
be mortality or some other measure like HCC stage. The
risk of meeting the waiting list endpoint then becomes
the metric for prioritization.
Although the LT community recognized many condi-
tions other than HCC in which mortality risk does not
adequately define need for LT,7 few endpoint criteria
and even fewer risk models exist to help quantify this
need. A regional peer review system was established so
that expert opinion could be brought to bear on making
these assessments and currently these Regional Review
Boards (RRBs) prospectively review every case (other
than HCC within Milan Criteria) where the need for LT
is thought to be underestimated by the MELD/PELD
defined-mortality risk. However, because there are no
well-defined criteria and there has been no comprehen-
sive evidence review to establish guidelines to help
RRBs make these assessments, these judgments have
been largely based on individual RRB members’ expert
opinions. Several RRBs around the country have
adopted their own systems for making these judge-
ments but there is no consistent national protocol for
RRB process. In addition, a systematic examination of
the data elements required for better risk assessment
studies is required to improve the appropriate prioriti-
zation of these exceptional cases.
As part of ongoing organ allocation policy assessment
and development, the United Network for Organ Shar-
ing, the federal contractor for administration of the na-
tional Organ Procurement and Transplantation Net-
work, constituted an effort to evaluate the non-HCC
exceptional cases under the MELD/PELD liver alloca-
tion system. The MELD Exceptional Case Guideline
(MESSAGE) Committee and recent MESSAGE confer-
ence participants were charged with two main tasks in
an effort to improve ranking of candidates with these
exceptional diagnoses where the need for LT might be
defined by other endpoints. The specific goals in this
exercise were: (1) to identify conditions for which a
specific, objective, endpoint exists that defines need for
LT such that assignment of additional priority can be
automatic (without RRB peer review) and recommend
the amount of additional priority so assigned, and (2)
for those conditions where there is insufficient evi-
dence, to recommend specific, objective data elements
to be collected for individual conditions for which there
was insufficient evidence for granting increased prior-
ity.
Since HCC has been well addressed in other forums,
the MESSAGE subcommittee was directed to focus on
all other areas of exceptional diagnoses and RRB re-
quests for priority upgrades and state where there was
no data and identify data elements to be collected. The
MESSAGE subcommittee presented the results of their
literature review at an international meeting of experts
in the field held March 1 and 2, 2006, in Chicago, IL, at
which final recommendations were formulated. The
preceding articles in this supplement summarize these
deliberations. In this article, we summarize the conclu-
sions reached for individual exception conditions re-
garding LT waiting-list endpoints, the priority magni-
tude recommended, and the data required to develop
endpoints in cases where no clear endpoint has been
defined. We will offer some conclusions for future de-
velopment of policy to address exceptional cases.
SPECIFIC RECOMMENDATIONS
Current evidence and expert opinion regarding excep-
tional conditions where MELD/PELD alone may be in-
adequate for prioritization for LT are listed in Table 1.
Waiting list endpoints are indicated for all exceptional
case diagnoses. For most diagnoses, a risk of mortality
is deemed most appropriate, but since the evidence
suggests that the MELD/PELD score does not ade-
quately measure wait-list removals as too ill, mortality
risk or risk of no liver disease end organ damage for
these cases, additional data are needed. Automatic as-
signment of priority is indicated based on sufficient
evidence, expert opinion, or established practice.
Ascites
Biggins et al.8 cite studies indicating that mortality risk
is the appropriate endpoint when considering ascites as
an additional criterion for assigning priority for LT.
These studies indicate that ascites is associated with
increased mortality risks but subjective measure-
ments, even those defined by the International Ascites
Club, are not dependent on intrinsic patient character-
istics and are more a reflection of physician practice
patterns/preferences and reporting biases. Serum so-
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Ascites Mortality risk Serum sodium 
MELD score
No There is inadequate evidence for increased
mortality to support increased priority in
most cases.





No Evidence for increased mortality risk is
confounded by subjective measures and
patient compliance issues. The West
Haven criteria are subjective.




No Quality of life justifications are not
sufficient for increased priority.








No Prospective application should include
specific contraindication to TIPS,
endoscopic, or medical treatments.
Hepatopulmonary
syndrome




Yes A correlation between progressive
hypoxemia and mortality is not well








No A correlation between progressive MPAP
and waiting list mortality needs to be
established in large prospective studies.
BCS Mortality risk None No MELD points define severity of disease for
chronic BCS. Acute BCS should use 1A
designation.
Pruritis Not justified None No Quality-of-life justifications are not
sufficient for increased priority.





Yes A liver biopsy sample documenting PH is


















Yes Evidence needs to be accumulated to
document increased waiting list disease
progression that results in dropout and
increased mortality.
Cystic fibrosis Mortality risk FEV1  40%
predicted
Yes/No Automatic priority increases justified for
patients listed for LT alone who have
progressive pulmonary deterioration
justified by documented increase in














No Neoadjuvant protocols must be approved
by UNOS/OPTN Liver Committee to meet
increased priority. Automatic upgrades
are only permissible for approved
neoadjuvant protocols. Dysplasia has no
evidence for increased waiting list death
or removal.
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dium in association with MELD score has shown im-
proved accuracy for estimating mortality risk, espe-
cially for patients with low MELD scores, although the
absolute increase in predictive value is small.9 The
United Network for Organ Sharing/Organ Procurement
Transplantation Network waiting list data collection
process has accumulated a large amount of serum so-
dium values and these data should be analyzed for
prospective validation in association with the MELD
score. At present, in the absence of a clear contribution
of objectively measured ascites to the mortality risk
defined by MELD, no automatic assignment of addi-
tional priority points can be made. There is little addi-
tional objective evidence that ascites changes the
MELD-defined mortality risk, especially at the higher
range of MELD scores where liver allocation is most
likely to occur, and most measures of severity of ascites
remain physician-specific. Therefore, there is little evi-
dence to support additional priority for patients with
severe ascites and those referred for RRB approval
should be extremely rare and unusual.
Hepatic Encephalopathy
Ham et al.10 rightfully point out that there are no pa-
tient-specific, well-documented objective measures of
hepatic encephalopathy (HE), although there are data
suggesting that HE (if consistently measured) can be
associated with increased mortality, independent of the
MELD score. Potential objective variables to be as-
sessed for future refinement of the contribution of HE to
mortality risk are: endotracheal intubation for airway
protection in severe HE, and/or increased intracranial
pressure. The West Haven Criteria are subject to ob-
server bias and are based on subjective assessments of
mental status. Endotracheal intubation is also depen-
dent on physician practice patterns. Thus, although
there is evidence for increased mortality risk for pa-
tients with chronic liver disease and HE, the lack of
objective methods for quantification of its severity
makes it extremely difficult to accept increased priority
for this condition in a consistent and equitable manner.
















No There is no evidence that cholangitis is
directly associated with waiting list
mortality risk. Predictors for septic
complications such as antibiotic
resistance would help RRBs select
patients likely to have waiting list
mortality or waiting list removal as too ill
to undergo LT.
Unusual tumor None Metastatic
survey; biopsy
data




















No Rare cases with multiple manifestations
result in lack of definitive evidence for
automatic upgrade. Prospective RRB
review is required on a case-by-case basis,
taking into account wait-list removal for
progression of non–liver-related organ
failure or injury and the documentation
that LT will obviate disease progression.
Small-for-size syndrome Mortality risk Biopsy Yes Expert opinion recommends automatic




Mortality risk Cardiac failure;
portal
hypertension
No Mortality risk is likely not reflected by
MELD/PELD because of lack of
deterioration in liver synthetic function.
Abbreviations: MELD, Model for End-Stage Liver Disease; MESSAGE, MELD Exception Study Group and Conference; ICP,
intracranial pressure; TIPS, transjugular intrahepatic portal systemic shunt; MPAP, mean pulmonary artery pressure; PVR,
pulmonary vascular resistance; RV, right ventricular; BCS, Budd-Chiari syndrome; PH, primary hyperoxaluria; PELD,
Pediatric End-Stage Liver Disease; BMI, body mass index; FEV1, forced expiratory volume at 1 second; LT, liver
transplantation; IRB, institutional review board; UNOS, United Network for Organ Sharing; OPTN, Organ Procurement
Transplantation Network; RRB, regional review board.
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matic increases in priority and case-by-case approvals
by the RRBs also should be extremely rare unless sup-
ported by intracranial pressure measurements or en-
dotracheal intubation justifications.
Polycystic Liver Disease
Polycystic liver disease rarely carries an increased mor-
tality risk, although these patients can have severe de-
terioration in their quality of life.11 There are many
nontransplant options that may temporarily or rarely,
permanently, relieve symptoms. In extreme cases, mal-
nutrition resulting from inanition and early satiety can
develop and profoundly impair affected patients’ im-
mune responses to infection and their ability to survive
surgery. There is insufficient evidence to warrant auto-
matic priority increases for patients with polycystic
liver disease. Individual prospective requests to RRBs
for increased priority should include information on
nutritional parameters and history of cyst infection.
Requests based on quality-of-life justifications cannot
be supported because there is no correlation with qual-
ity of life. Some regions have assigned a moderate in-
crease in priority to cases where severe starvation can
be documented by liver size and biochemical nutri-
tional parameters. A modest initial score can then be
increased by 2 or 3 points every 3 months until the
patient gets transplanted. This approach gives these
cases some increase in priority, but does not allow for
transplantation in such cases without substantial wait-
ing time, making it fair for all patients waiting.
Gastrointestinal Bleeding
Bleeding from increased portal pressure is a common
complication of chronic liver disease and has been as-
sociated with increased mortality in these patients.12
Although there are highly effective surgical and medical
treatments for acute portal hypertensive bleeding, there
are also contraindications to each of these measures.
Currently, there are no prospectively validated mea-
sures of the severity of bleeding or objective measures
for contraindications for interventions, although serum
bilirubin may be a helpful prognostic marker for suc-
cess of transjugular intrahepatic portal systemic shunt.
Because the vast majority of cases of portal hyperten-
sive bleeding can be controlled with nontransplant
measures, and there are no well-established, objective,
patient-specific measures of refractory bleeding, no au-
tomatic increase in priority can be justified at this time.
Individual prospective applications to RRBs for in-
creased priority based on recurrent bleeding should
include documentation of contraindications to medical
and surgical therapy, quantity of blood transfused over
a given period of time, use of mechanical tamponade
devices, and requirement for endotracheal intubation.
Hepatopulmonary Syndrome
Hepatopulmonary syndrome is increasingly diagnosed in
patients with cirrhosis. Established MELD/PELD liver al-
location policy allows increased priority, in theory, be-
cause the pulmonary component of this disease conferred
a risk of dropping out that was beyond that calculated by
the MELD score alone. Fallon et al. indicate that there are
data suggesting that progressive hypoxemia in patients
with documented intrapulmonary shunting and cirrhosis
is associated with increased mortality, but these results
are derived from small retrospective analyses.13 Hypox-
emia appears to be an appropriate waiting list variable in
that it is patient specific, easily and objectively measured,
and has been associated with mortality. The degree to
which this is independent from MELD only defined risk
remains to be established and incorporating PaO2 with
MELD might be feasible. Based on these data and the
experience with the current MELD/PELD-based policy for
increased priority for Hepatopulmonary syndrome pa-
tients with PaO2  60 mmHg and documented intrapul-
monary shunting with no other cause for the pulmonary
disease found, expert opinion recommends an automatic
increase in MELD priority calibrated to the severity of
hypoxemia. Additional data on pulmonary parameters
will be helpful in better defining the limits of waiting list
dropout and LT success for these patients.
Portopulmonary Hypertension
Portopulmonary hypertension (POPH) has been associ-
ated with increased rates of posttransplant mortality
and untreated, the median survival is approximately 18
months. The degree to which the severity of liver disease
and the severity of the pulmonary hypertension each
contribute to the poor outcomes before and after liver
LT remains poorly understood, but MELD scores do
seem to correlate well with the degree of portopulmo-
nary hypertension.14 Experts recommend that screen-
ing for pulmonary hypertension with echocardiography
should be required as many cases of portopulmonary
hypertension are diagnosed only at the time of anesthe-
sia induction for LT. In addition, right heart catheter-
ization is required to accurately characterize the por-
topulmonary hypertension so that measurements of
pulmonary systolic, diastolic, vascular resistance, oc-
clusion pressure, and cardiac output can be performed.
Mean pulmonary artery pressure (mPAP) is emerging as
a potentially acceptable waiting list variable since it is
objective and patient-specific and may be correlated
with pretransplant mortality, but more data needs to be
accumulated including the role of prostacyclin ana-
logue treatment in altering the pulmonary hemody-
namics and waiting list mortality.
Expert opinion recommends that increased priority is
justified for patients with documented mean pulmo-
nary artery pressure  35mmHg (prior to treatment)
with an estimated 26 MELD points awarded. However,
since there is clear evidence that patients with mPAP 
45 mmHg have extremely poor post transplant out-
comes,15 every effort should be made to treat this de-
gree of POPH prior to LT. Cases where the mPAP re-
mains  45 mmHg despite treatment should receive
extra priority only in extremely unusual instances,
since the results with LT remain very poor for these
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patients. Requests for increased priority for POPH cases
should include documentation of the mPAP and pulmo-
nary vascular resistance and the effects of any treat-
ment given to reduce the mPAP prior to LT. Because
there is little data on the magnitude of increased risk
related to MPAP, quantification of increased need on
the basis of MPAP remains arbitrary at this time.
Budd-Chiari Syndrome
Indications for LT for patients with Budd-Chiari syn-
drome (BCS) generally fall into two categories. Most
patients develop progressive cirrhosis and portal hyper-
tensive symptoms that, ultimately result in loss of he-
patic synthetic function. In rare cases, BCS can present
with features of fulminant hepatic failure where emer-
gent intervention is required. The available evidence
suggests that patients with chronic progressive BCS
are well served by the MELD score as the parameters
associated with mortality cited in previous studies
closely parallel those included in the MELD score.16
Patients with acute, fulminant BCS should be priori-
tized by using acute liver failure polices such as the 1A
designation. Thus, exception points should not be nec-
essary for patients with BCS.
Pruritus
There have been applications to RRBs justifying in-
creased priority on the waiting list due to intractable
pruritus. While this can be an aggravating problem,
there are no data associating pruritus with waiting list
mortality or premature dropout from the list.17 While
pruritus may be a patient-specific complaint, there are
no measures developed for objectively quantifying this
problem. For all of these reasons, we conclude that
there is no evidence to support automatic or prospec-
tive RRB approval for increased priority based on pru-
ritus symptoms.
Primary Hyperoxaluria
Primary hyperoxaluria (PH) causes progressive deposi-
tion of oxalate in affected individuals that eventually
results in renal failure. In this inborn error of metabo-
lism, the deficient enzyme resides in the liver and fail-
ure to correct the enzymatic defect results in continued
oxalate deposition that can result in cardiac and other
peripheral tissue destruction in addition to the inevita-
ble oxalate stones and subsequent renal failure. Gen-
erally, PH patient’s mortality risk is not defined by their
liver disease and is not reflected by their MELD/PELD
score. Their need for LT is defined by progressive ox-
alate deposition. The development of renal failure in
patients with PH has been associated with increased
mortality before transplantation, as has extremely
young age, but there are no quantitative studies iden-
tifying risk factors for dropping out from the waiting
list. Since the introduction of the MELD/PELD system,
approximately 8 or 9 patients with PH have received
liver transplants per year.
Expert opinion has determined that analysis of liver
biopsy samples alone (a patient-specific variable) doc-
umenting the PH enzymatic defect is sufficient to justify
automatic award of increased priority above the calcu-
lated MELD/PELD score without prospective RRB re-
view.18 The recommended amount of increased priority
for patients with PH, however, is not based on a quan-
titative assessment of increased risk. In addition, be-
cause PH patients with established renal failure as de-
fined by the need for renal replacement therapy have
increased mortality risk, expert opinion recommends
automatic award of additional increased priority, again
without solid evidence for determining the magnitude of
increased priority. Children less than one year of age
with this condition have the highest mortality risk while
waiting and therefore, should be allowed an automatic
award of 40 PELD points. The very few cases overall,
and rare numbers of small children with PH will make
statistical validation of dropout risks difficult.
Familial Amyloid Polyneuropathy
Familial amyloidotic polyneuropathy is another enzyme
defect that results in progressive deposition of amyloid
into various tissues. In the most common type, there is
a point mutation in a primarily hepatic enzyme that
results in amyloid deposition into neurologic, cardiac,
and ophthalmic tissues that is ultimately fatal. Liver
transplantation restores normal enzyme function and
can partially resolve the end-organ dysfunction. These
patients’ mortality risk is not dependent on their liver
disease and the MELD score is not reflective of their
need for LT. There are no good analyses of factors as-
sociated with mortality or waiting-list dropout in these
patients, although cardiac parameters (i.e., ventricular
wall thickness, ejection fraction, arrhythmias, and New
York Heart Association class), nutritional parameters,
and the polyneuropathy disability score have the poten-
tial to define a risk of waitlist removal analogous to
MELD/PELD for other candidates because they are pa-
tient-specific and reasonably objective variables. These
diagnoses are patient-specific, reasonably objective,
and these variables would be good candidates for future
liver allocation policy adjustments.19
The original MELD/PELD-based liver allocation policy
recognized the lack of natural history data for patients
with familial amyloidotic polyneuropathy and the diffi-
culty of correlating risk of dropout for these patients with
the standard MELD risk of mortality. Arbitrarily, a MELD
priority equivalent to 15% risk of 3-month mortality was
assigned. The current expert opinion recommends that
this be automatic if the application contains biopsy-
proven evidence of amyloid deposition and documenta-
tion of the most common TTR gene mutations, but recog-
nizes that this amount of increased risk is still completely
arbitrary. There are no organized efforts for collecting
other data such as echocardiographic variables or poly-
neuropathic disability or nutritional scores that are pos-
sibly associated with deterioration beyond a transplant-
able stage, and no endpoints defining futile transplant
stage have been developed.
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Cystic Fibrosis
Cystic fibrosis (CF) results in progressive pulmonary
and liver disease. The liver disease resembles chronic
biliary cirrhosis. CF patients with isolated liver disease
develop all of the manifestations of chronic cirrhotic
liver disease and their need for LT is reasonably esti-
mated by their mortality risk defined by MELD/PELD.
However, the evidence suggests that CF patients with
liver disease who also have progressive pulmonary dis-
ease face increased risks of death before (and after) LT
and some will require combined liver-lung transplant
procedures.20 Forced expiratory volume (FEV1), an ob-
jective, patient-specific measure, has been helpful iden-
tifying CF patients with pulmonary disease and can be
used to screen waiting LT candidates. Formal collection
of the FEV1 data has not been accomplished by the
United Network for Organ Sharing/Organ Procurement
Transplantation Network data collection system but the
evidence is strong enough to justify automatic award of
increased priority for patients waiting for LT alone with
progressive pulmonary disease due to CF. Quantifica-
tion of the amount of increased priority is arbitrary at
this time and how patients in need of combined liver-
lung transplantation should be accurately ranked will
require many more cases to be accumulated before sta-
tistical validity can be achieved. The impact of new lung
allocations policies also needs to be monitored to see if
those policies obviate the need for any additional auto-
matic MELD points to be assigned on the basis of pro-
gressive liver disease and its associated risks.
Cholangiocarcinoma and Biliary Dysplasia
Recent neoadjuvant protocols that include operative
staging for cholangiocarcinoma confined to the hepatic
hilum have improved the previously dismal success
rates for LT in patients with this condition.21 However,
these results have only been achieved via rigorous ap-
plication of well-designed protocols. Current evidence
suggests that, for properly-selected patients with pri-
mary sclerosing cholangitis-associated cholangiocarci-
noma in whom surgical resection is not possible, LT
offers a reasonable chance at cure and that alternative
therapies have little benefit. In addition, tumor recur-
rence rates are high for patients fulfilling protocol cri-
teria who come to LT longer than 140 days after listing.
Unfortunately, published reports do not describe pre-
transplant predictors of cancer recurrence other than
waiting time. The results from these prospective, neo-
adjuvant protocols provide evidence for justification of
increased priority for patients enrolled in these trials
especially in light of the poorer results obtained when
patients waiting longer. Though the recommended
quantity of increased priority has not been calibrated to
the risk of dropout as yet, this should become possible
as more data accumulates.
Cholangitis
Bacterial cholangitis is a common problem in patients
with structural biliary disease and can cause severe
complications. However, there is essentially no evi-
dence for cholangitis being associated with mortality
risk.22 Patients who have cholangitis and recurrent
bacteremia or its complications (i.e., osteomyelitis, en-
docarditis) may be ineligible to receive LT and thus may
be at increased risk of dropout, although this has not
been conclusively proven. For this reason, expert opin-
ion recommends that prospective RRB application be
allowed for such cases and that an increased priority
can be awarded if specific criteria are met. Again, the
amount of increased priority is not based on quantified
endpoint risks, since neither an endpoint nor the risk
factors have been established.
Unusual Tumors
There are several different types of non-HCC tumors,
primary or metastatic, for which LT has been reported.
However, these are very few in number and there is
essentially no data on dropout risk for these cases. For
this reason, automatic award of increased priority can-
not be justified. Metastatic tumors where the primary
disease has not been controlled generally have very
poor outcomes and should not receive increased prior-
ity through prospective review. Other cases should re-
ceive individual attention via the RRB process. Expert
opinion recommends that primary hepatic hemangio-
epitheliomas, carcinoid tumors confined to the liver
and multiple hepatic adenomas in glycogen storage dis-
ease are acceptable cases for prospective RRB applica-
tions and review.23 The extremely small number of
these cases makes it unlikely that enough data will be
obtained for evidence-based decision-making regarding
correct priority ranking for these patients on the basis
of their dropout rates.
Unusual Metabolic Diseases
All of these conditions are rare, which makes develop-
ment of evidence-based recommendation on prioritizing
these patients nearly impossible.24 Some defects such
as Wilson’s disease, hemochromatosis, and alpha-1-
antitrypsin disease result in progressive liver fibrosis
and cirrhosis and biliary transport diseases (e.g.,
Byler’s disease) result in jaundice and secondary biliary
cirrhosis. In these cases, the MELD/PELD score is an
adequate reflection of the need for LT. For other condi-
tions where there is no structural liver disease, liver-
based mortality endpoints are not appropriate and
other parameters such as risk of neurologic deteriora-
tion, risk of renal failure, nutritional compromise, hy-
perammonemia, and HCC risk should be taken into
account. There is insufficient evidence to justify auto-
matic upgrade by RRBs for these conditions and they
should be managed on a case-by-case basis. Several of
these conditions qualify for advancement to status 1B
priority.
Small-For-Size Syndrome
Small-for-size syndrome develops after primary living-
donor transplantation of a liver graft that either is of
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insufficient liver mass for the recipient or has a signif-
icant mismatch of vascular inflow to outflow. In both
cases, severe synthetic dysfunction occurs, which has
been associated with increased risk of death.25 There
are no data available indicating whether these patients
have different risks of dropout relative to other cases
listed for retransplantation or whether the MELD/
PELD score underestimates these patients’ mortality
risk relative to other waiting LT candidates. It is clear,
however, that mortality risk is the correct waiting list
endpoint for these cases.
In the absence of these data, expert opinion has recom-
mended that cases where a partial graft has been trans-
planted in which hyperbilirubinemia, coagulopathy,
and/or ascites is evident in the early posttransplant pe-
riod should receive automatic increase in priority equal to
50% mortality risk. There are no quantitative data indi-
cating that this estimate accurately reflects the true de-
gree of increased risk these recipients face and such data
needs to be prospectively collected.
Hereditary Hemorrhagic Telangiectasia
Although hereditary hemorrhagic telangiectasia, also
known as Rendu-Osler-Webber Disease, is a systemic
disease, the liver is often the major area of involvement.
These cases can develop high output cardiac failure
and portal hypertension from the arteriovenous malfor-
mation in the liver. There are a few reported series of LT
performed for this condition with varying success rates
related to other comorbidities and degree of extra-he-
patic disease. Natural history studies also indicate that
although some cases progress to fatal outcomes, other
cases regress spontaneously with or without medical or
surgical intervention. Thus, mortality risk progression
may be the correct waiting list endpoint for hereditary
hemorrhagic telangiectasia, but the lack of documented
prognostic risk factors makes prediction of this impos-
sible at this time. For this reason, there is insufficient
evidence to justify automatic increases in MELD/PELD
score priority and these cases should be evaluated by
RRBs on an individual basis. Since these patients usu-
ally do not develop synthetic liver failure, it is unlikely
that their MELD/PELD scores will adequately estimate
their mortality risk. However, since these are rare
cases, there is no available evidence on which to base a
quantification of mortality risk at this time.
DISCUSSION
Ideally, medical decision-making, especially decisions
of the magnitude of liver allocation, would be made with
the highest quality clinical evidence derived from ran-
domized controlled trials and would be consistent
through UNOS. However, obtaining this kind of evi-
dence is obviously not possible in the field of liver allo-
cation. The MELD/PELD allocation system for stan-
dard cases is based mostly on level 2 evidence, derived
from retrospective and prospective case-controlled and
cohort studies. More problematic as far as evidence-
based policy making is concerned are these so-called
“exceptional cases”. Many of these conditions, as out-
lined above, occur so infrequently that valid cohort
studies producing statistically or clinically relevant re-
sults that are reproducible will never be possible and
prioritization policy will always have to rely on expert
opinion alone. However, as indicated above for some
conditions, there are potential endpoints that might be
addressed and data that might be accumulated to pro-
vide a more objective assessment of these patients’ need
for transplantation.
For many of these cases, there may be enough occur-
rences where mortality risk may serve as a reasonable
prioritization endpoint and could be easily equated to
the MELD/PELD score mortality risk estimates em-
ployed for the standard cases. Unfortunately, there is a
near complete lack of data from which risk factors that
would accurately define the mortality risk, or wait list
removals for progressive disease, for these various con-
ditions might be developed and validated. Outside data
collection efforts funded by entities with interests in
specific diseases should be sought as in the case of the
pulmonary complications in hepatic disease effort
funded by the National Institutes of Health. Moreover,
in the majority of these cases, factors other than those
included in the MELD/PELD score are likely to play a
role, and a concerted effort to collect these data will be
necessary. Possible data elements to be addressed are
included in Table 1. For most cases a risk of mortality is
deemed to be most appropriate, but since the evidence
suggests that the MELD/PELD score does not ade-
quately measure mortality risk for these cases, addi-
tional data are needed. Automatic assignment of prior-
ity is indicated based on sufficient evidence, expert
opinion, or established practice as indicated. For a few
of the conditions (e.g., small-for-size syndrome),
MELD/PELD might be a reasonable estimate of mortal-
ity risk and these instances should be analyzed and
validated.
For other conditions, mortality risk is not an appro-
priate estimation of LT need and risk for waiting list
removals and progression of nonliver-related diseases
must be considered.26 We have suggested potential
endpoints already indicated in the literature that might
serve to prioritize these patients. For example, using
the polyneuropathy disability score, which is somewhat
analogous to the MELD/PELD score in patients with
familial amyloid polyneuropathy, might be a more con-
tinuous and evidence-based method for assigning pri-
ority instead of the arbitrarily designed methods we
currently use. Incorporating some measure of hypoxia
with the appropriate coefficients into a MELD score for
patients with hepatopulmonary syndrome might also
be appropriate and more reflective of need than the
arbitrary, one-size-fits-all method we currently use.
What is clear though, is that quality-of-life endpoints
alone are not sufficient for prioritization because they
are subjective and cannot be fairly equated to mortality
risk.27
In all of the cases where automatic priority increases
are recommended, a single uniform amount of MELD/
PELD points to be awarded has been advocated. These
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black and white distinctions generally are not reflective
of the spectrum of clinical disease and varying rates of
progression and do not adequately characterize the
need for LT, regardless of the endpoint used. For these
reasons, less arbitrary, more granular, continuous
stratifications of LT need must be developed to more
precisely represent the actual situations.
All of these refinements, however, require a much
more standardized data collection system. Developing a
national review board process that uses standardized
data collection methods and analysis protocols and
that assigns priority on a consistent basis seems to be
mandatory to achieve these goals. Only with this stan-
dardized approach can consistent priority be assigned,
either by RRBs applying national standards to the local
reality or using a national system that accounts for
regional variations. The MESSAGE study group has
provided an excellent synthesis of the available data for
these diagnostic categories, but just as importantly, it
has clearly illuminated the significant evidence gaps
that exist. Closing these gaps may not be possible for
some of the rarer conditions, but our patients deserve a
much more evidenced-based approach to prioritizing
most of these cases. This can only be achieved with a
rational approach on a national level that targets the
more common exceptional diagnostic groups for fo-
cused data collection, similar to the HCC example cited
above. Waiting list endpoints need to be designed and
risk factors for progression to these endpoints must be
identified.
The MESSAGE committee members and the mem-
bers of the Liver and Intestinal Committee who were
involved in this project would like to emphasize that the
Regional Review Boards across the country have held
widely divergent opinions on which conditions should
receive additional MELD points if any, and on how
much priority should be given for exceptional case re-
quests. The purpose of the MESSAGE group’s work was
to provide a consistent, evidence-based approach to
listing of patients with additional MELD points across
the United Network for Organ Sharing regions.
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